Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species-Reference-Cited by-同舟云学术

Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species

Published:2021-02-19 Issue:2 Volume:73 Page:597-678
ISSN:0031-6997
Container-title:Pharmacological Reviews
language:en
Short-container-title:Pharmacol Rev

Author:

van Groen B. D.,Nicolaï J.^ORCID,Kuik A. C.,Van Cruchten S.,van Peer E.,Smits A.,Schmidt S.,de Wildt S. N.,Allegaert K.,De Schaepdrijver L.,Annaert P.^ORCID,Badée J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference218 articles.

1. Lobular distribution and variability in hepatic ATP binding cassette protein B1 (ABCB1, P-gp): ontogenetic differences and potential for toxicity;Abanda;Pharmaceutics,2017

2. Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity

3. Western Blots versus Selected Reaction Monitoring Assays: Time to Turn the Tables?

4. Biochemical changes of catechol-O-methyltransferase during development of human liver;Agathopoulos;Pediatrics,1971

5. Evaluation of the Assumptions of an Ontogeny Model of Rat Hepatic Cytochrome P450 Activity

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of enteroids derived from children and adults to study age-dependent differences in intestinal CYP3A4/5 metabolism;European Journal of Pharmaceutical Sciences;2024-10

2. Physiologically-based pharmacokinetic modelling to investigate the effect of CYP3A4/3A5 maturation on tacrolimus pharmacokinetics in paediatric HSCT patients;European Journal of Pharmaceutical Sciences;2024-10

3. Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing;Journal of Antimicrobial Chemotherapy;2024-08-01

4. Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies;Pharmaceutics;2024-07-26

5. PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors;Clinical Pharmacology & Therapeutics;2024-07-18